If you or a loved one was prescribed and took Pradaxa (dabigatran etexilate) and experienced severe bleeding or other serious side effects, you may be entitled to compensation in a Pradaxa lawsuit.
Pradaxa (dabigatran etexilate), manufactured by Boehringer Ingelheim Pharmaceuticals, is commonly prescribed anticoagulant used to prevent strokes and blood clots in patients suffering from atrial fibrillation, an abnormal heart rhythm. Doctors also prescribe Pradaxa to treat and control blood clots occurring in the lungs (pulmonary embolism) and the legs (deep vein thrombosis).
Because Boehringer Ingelheim marketed Pradaxa as safe and effective, doctors wrote millions of prescriptions for the drug. However, since the Pradaxa's approval by the U.S. Food and Drug Administration (FDA) in 2010, several patients have reported severe bleeding events. Some of the side effects Pradaxa users have reported include, but are not limited to:
- Gastrointestinal bleeding
- Rectal bleeding
- Brain bleeding
The lawsuits allege that had doctors been provided with sufficient warnings of Pradaxa's potential side effects or had Boehringer Ingelheim identified an effective antidote prior to marketing the drug, patients may have been able to make a more informed decision.
If you suffered side effects from using Pradaxa, the Kishish Law Group can help. Contact us now for a free and confidential case evaluation by using our contact form or calling us toll-free at 1 (888) 609-4664 .
Some Pradaxa Lawsuits Settled for $650 Million, but Litigation Continues
After patients reported bleeding events after taking Pradaxa, many filed lawsuits against Pradaxa's manufacturers. Most of these lawsuits were combined into multidistrict litigation. In May 2014, Boehringer Ingelheim announced that they had resolved 4,000 of these claims, settling for $650 million. The pharmaceutical company continued to advocate for their drug, saying in a statement, "We continue to stand resolutely behind Pradaxa® and believed from the outset that the plaintiffs’ claims lacked any merit. Notwithstanding our strong belief that we would prevail in these lawsuits, this settlement allows our company to avoid the distraction and uncertainty of protracted litigation over years and years." In addition, they added that the U.S. F.D.A. maintains that Pradaxa has a "positive risk-benefit profile."
Although future plaintiffs will not be entitled to benefit from discovery done in the multidistrict litigation cases, lawyers continue to pursue Pradaxa cases following the settlement, claiming that Boehringer Ingelheim's warnings about the risk of dangerous bleeding with Pradaxa use remain inadequate. At the time of the settlement, doctors had prescribed Pradaxa to 850,000 patients in the U.S. with sales totaling over $2 billion.
Do I have a Pradaxa lawsuit?
The Kishish Law Group is committed to seeking justice for you and your loved ones. We believe that you deserve fair compensation for your suffering and we will work tirelessly to achieve that goal. If you or a loved one suffered due to taking Pradaxa, we want to know.
DISCLAIMER: No attorney client relationship will exist between you and our firm until we enter into a signed Retainer/Services Agreement. Completion of this document is for informational purposes only and does not constitute a Retainer/Services Agreement. The information you obtain at this site is not, nor is it intended to be, legal advice. Contacting us does not create an attorney-client relationship. In some jurisdictions this website may be considered lawyer advertising. You should consult an attorney for advice regarding your individual situation. Click here for more information.
Speak with a Pradaxa Lawyer
If you or a loved one were prescribed and took Pradaxa (dabigatran etexilate) and suffered injuries or serious side effects, you may be entitled to compensation.
Contact a lawyer today for a free and confidential legal consultation.
- February 18, 2018
Invokana Lawsuits Rise, First Trial of Alleged Amputation Set for September
- June 12, 2017
Invokana Side Effects and Diabetic Ketoacidosis
- June 8, 2017
SGLT2 Inhibitors, like Invokana, Found to Double Risk of Diabetic Ketoacidosis
- May 23, 2017
Diabetes Drug Invokana Linked to Amputation Risk
- May 17, 2017
Over 30% of Drugs Had Safety Problems After FDA Approval